Get the Stockscreener App
9.53
0.21%
-0.02
Anavex Life Sciences Corporation stock is traded at $9.53, with a volume of 750.35K.
It is down -0.21% in the last 24 hours and down -14.68% over the past month.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.
See More
Previous Close:
$9.55
Open:
$9.5
24h Volume:
750.35K
Relative Volume:
0.74
Market Cap:
$818.57M
Revenue:
-
Net Income/Loss:
$-43.16M
P/E Ratio:
-17.33
EPS:
-0.55
Net Cash Flow:
$-29.31M
1W Performance:
-4.17%
1M Performance:
-14.68%
6M Performance:
+14.13%
1Y Performance:
+55.46%
1-Day Range:
$9.42
$9.76
1-Week Range:
$9.265
$10.03
52-Week Range:
$4.9301
$14.44
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
Name
Anavex Life Sciences Corporation
Sector
Industry
Phone
844-689-3939
Address
630 5TH AVENUE, NEW YORK
Compare AVXL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corporation
|
9.53 | 823.72M | 0 | -43.16M | -29.31M | -0.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Sep-23-21 | Initiated | BTIG Research | Buy |
| Dec-16-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-28-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-27-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-18-19 | Initiated | Janney | Buy |
| May-16-18 | Resumed | Maxim Group | Buy |
| Mar-08-18 | Initiated | ROTH Capital | Buy |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Feb-07-17 | Initiated | Noble Financial | Buy |
| Mar-29-16 | Initiated | FBR Capital | Outperform |
View All
Anavex Life Sciences Corporation Stock (AVXL) Latest News
Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer's Disease - MarketScreener
Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer’s Disease - The Manila Times
Anavex Life Sciences Corp. Announces Positive Results for Blarcamesine in Preventing Cognitive Decline in Alzheimer's Disease Model - Quiver Quantitative
Anavex Life Pre-Treatment Prevented Cognitive Impairment In Animal Model of Alzheimer's Disease, New Publication Shows - Benzinga
Complete Prevention of Memory Loss: Anavex's Alzheimer's Drug Shows Breakthrough in Animal Study - Stock Titan
Anavex Life Sciences Corp. Attempts Reversal From Key Support2025 Short Interest & Trade Opportunity Analysis - newsimpact.co.kr
Can volume confirm reversal in Anavex Life Sciences Corp.Weekly Investment Report & Long-Term Safe Return Strategies - Newser
Why Anavex Life Sciences Corp. is moving todayJuly 2025 PreEarnings & Verified Technical Trade Signals - Newser
Visual analytics tools that track Anavex Life Sciences Corp. performanceEarnings Summary Report & Free Weekly Chart Analysis and Trade Guides - Newser
Real time social sentiment graph for Anavex Life Sciences Corp.Portfolio Performance Report & Daily Volume Surge Signals - Newser
Risk adjusted return profile for Anavex Life Sciences Corp. analyzedEarnings Recap Report & Smart Money Movement Tracker - Newser
Regression analysis insights on Anavex Life Sciences Corp. performanceMarket Volume Report & Detailed Earnings Play Strategies - Newser
Is Anavex Life Sciences Corp. a candidate for recovery playEarnings Recap Summary & Fast Entry High Yield Tips - Newser
What technical models suggest about Anavex Life Sciences Corp.’s comebackEarnings Trend Report & Expert Approved Momentum Ideas - Newser
What data driven models say about Anavex Life Sciences Corp.’s futureJuly 2025 Drop Watch & Daily Profit Focused Stock Screening - Newser
Fibonacci Retracement Aligns with Support in Anavex Life Sciences Corp.2025 Technical Patterns & Precise Buy Zone Tips - 선데이타임즈
Is Anavex Life Sciences Corp. Forming a Bottom Pattern2025 Market WrapUp & Free Daily Entry Point Trade Alerts - sundaytimes.kr
Chart overlay techniques for tracking Anavex Life Sciences Corp.Earnings Performance Report & Risk Controlled Stock Pick Alerts - Newser
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q3 2025 Earnings Call Transcript - MSN
Anavex Life Sciences (NASDAQ:AVXL) Given “Buy” Rating at D. Boral Capital - Defense World
LPL Financial LLC Boosts Stake in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
PNC Financial Services Group Inc. Has $495,000 Stake in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Anavex Life Sciences Amends Executive Employment Contracts - MSN
Anavex Life Sciences Corp (AVXL) Q3 2025 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance
Anavex Life Sciences Corp (AVXL) Q3 2025 Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders - ACCESS Newswire
Anavex: As The EMA Decision Nears, Key Risks Outweigh The Hype (NASDAQ:AVXL) - Seeking Alpha
Anavex Life Sciences: Fiscal Q3 Earnings Snapshot - Greenwich Time
Context Therapeutics Inc. shares fall 1.47% premarket after Anavex Life Sciences reports fiscal 2025 third quarter results. - AInvest
Anavex Life Sciences Reports Q3 2025 Financial Results - TipRanks
Can a trend reversal in Anavex Life Sciences Corp. lead to recoveryChart Signals & High Accuracy Swing Trade Signals - Newser
Achieve Life Sciences, Inc. shares rise 2.42% after-hours following positive earnings report. - AInvest
Anavex Life Sciences shares fall 4.76% intraday after reporting a wider fiscal Q3 loss. - AInvest
Earnings call transcript: Anavex Life Sciences Q3 2025 sees R&D drop - Investing.com
Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update - The Globe and Mail
Anavex Life Sciences Corp. Q3 Loss Increases, Misses Estimates - Nasdaq
Anavex Life Sciences Fiscal Q3 Loss Widens - MarketScreener
Anavex Life Sciences Corp. Reports Q3 Fiscal 2025 Financial Results and Webcast Announcement - Quiver Quantitative
Earnings Flash (AVXL) Anavex Life Sciences Posts Fiscal Q3 Net Loss $0.16 a Share, vs. FactSet Est of $0.14 Loss - MarketScreener
Anavex Reports Breakthrough: Oral Alzheimer's Drug Maintains Benefits After 4 Years as Cash Position Tops $100M - Stock Titan
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Acquired by Zurcher Kantonalbank Zurich Cantonalbank - Defense World
How high can Anavex Life Sciences Corp. stock goRSI and MACD Signal Summary with Trends - Newser
Understanding Anavex Life Sciences Corp.’s price movementSmart Trade Mapping with Entry Details - Newser
Why Anavex Life Sciences Corp. stock attracts strong analyst attentionSwing Watchlist With Tight Stop Placement - Newser
Sector ETF performance correlation with Anavex Life Sciences Corp.Stock Entry Points Based on Technicals - Newser
Historical volatility pattern of Anavex Life Sciences Corp. visualizedEquity Portfolio Outlook and Performance Summary - Newser
Published on: 2025-08-10 02:07:10 - Newser
Can Anavex Life Sciences Corp. recover in the next quarterROI Focused Setup Screener With Exit Markers - Newser
How Resilient Is Anavex Life Sciences Corp. Stock During Economic DownturnsFree Risk Controlled Short Term Trade Plans - Newser
Is Anavex Life Sciences Corp. stock reversal real or fakeIntraday Price Forecast Using Volume Models - Newser
Will Anavex Life Sciences Corp. outperform the marketVolume Spike Detection for Early Breakouts - Newser
Anavex Life Sciences Corporation Stock (AVXL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anavex Life Sciences Corporation Stock (AVXL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MISSLING CHRISTOPHER U | President and CEO |
Mar 24 '25 |
Option Exercise |
0.92 |
500,000 |
460,000 |
1,750,210 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):